GlaxoSmithKline, SK bioscience start final trial of COVID-19 jab

BRITAIN – British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have announced the commencement of final stage trials of a Covid-19 jab after positive early results. The vaccine is facing a Phase 3 clinical trial to assess its safety and immunogenicity when compared with AstraZeneca’s Covid-19 vaccine, the two companies said in a joint statement. GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford University despite having little prior experience in vaccine development. The new jab combines SK…

Read More

South Korea on alert for new Delta Plus COVID-19 variant

SOUTH KOREA – South Korea has detected its first two cases of the new Delta Plus COVID-19 variant, the Korea Disease Control and Prevention Agency (KDCA) has said, as the country battles with its fourth wave of infections. The Delta Plus variant is a sub-lineage of the Delta variant first identified in India, and has acquired the spike protein mutation called K417N, which is also found in the Beta variant first identified in South Africa. The variant, was first reported in a Public Health England bulletin on June 11. Reports…

Read More

SK Bioscience submits its COVID vaccine for phase 3 clinical trial as South Korea grapples with surging delta variant

SOUTH KOREA – SK Bioscience has submitted its application for the phase 3 clinical trials of its COVID vaccine, GBP510, to the to the Ministry of Food and Drug Safety (MFDS). GBP510, a COVID-19 vaccine candidate supported by Bill & Melinda Gates Foundation (BMGF) and Coalition for Epidemic Preparedness Innovations (CEPI) and co-developed with the Institute for Protein Design (IPD) at the University of Washington will become the first COVID vaccine developed in Korea to be submitted to MFDS. The company also plans to apply for phase 3 clinical trial…

Read More